Skip to main content

Navigation group

Type at least 3 characters
79 articles

Articles

Original Research

Accepted on 26 Sep 2023

ADALIMUMAB BIOSIMILAR ABP 501 IS EQUALLY EFFECTIVE AND SAFE IN LONG-TERM MANAGEMENT OF INFLAMMATORY BOWEL DISEASES PATIENTS WHEN USED AS FIRST BIOLOGIC TREATMENT OR AS REPLACE OF THE ADA ORIGINATOR FOR A NON-MEDICAL REASON

in Therapy in Gastroenterology

  • Giammarco Mocci
  • Arianna Cingolani
  • Giorgia Orrù
  • Carla Felice
  • Francesca Maria Onidi
  • Gianmarco Lombardi
  • Davide Checchin
  • Raffaele Colucci
  • Laurino Grossi
  • Antonio Ferronato
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1218228

Original Research

Published on 14 Sep 2023

Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study

in Gastrointestinal Infection

  • Anya Kiattiweerasak
  • Natsuda Aumpan
  • Soonthorn Chonprasertsuk
  • Bubpha Pornthisarn
  • Sith Siramolpiwat
  • Patommatat Bhanthumkomol
  • Pongjarat Nunanan
  • Navapan Issariyakulkarn
  • Varocha Mahachai
  • Yoshio Yamaoka
Efficacy and safety of Lacticaseibacillus rhamnosus R0011 and Lactobacillus helveticus R0052 as an adjuvant for Helicobacter pylori eradication: a double-blind, randomized, placebo-controlled study
Frontiers in Gastroenterology
doi 10.3389/fgstr.2023.1245993
  • 352 views